The drugmaker moved tozorakimab, an anti-IL-33 monoclonal antibody, into phase 2b in DKD in 2019 in response to evidence that inflammation plays a role in disease. Biomarkers of inflammation correlate to poor outcomes and mortality, and biopsies show IL-33 is upregulated, fueling hopes that inhibition of the pathway could reduce kidney damage.
AstraZeneca wrapped up the phase 2b, which administered tozorakimab in combination with its kidney disease drug Farxiga, last year and began analyzing whether the investigational molecule improved the urine albumin:creatinine ratio by more than placebo. The company is yet to share the results but used its fourth-quarter earnings to reveal it discontinued the trial because of efficacy.
After seeing the data, AstraZeneca removed tozorakimab in DKD from its phase 2 pipeline. The action was the only removal of a new molecular entity disclosed in the quarterly update, with all the other changes covering life cycle management of approved products.
Talking to investors on a third-quarter earnings call in November, Sharon Barr, executive vice president of biopharmaceuticals R&D at AstraZeneca, called tozorakimab “a strong contender” that “is differentiated [from] competitors because it is able to inhibit both the ST2 and the RAGE/EGFR pathways.”
AstraZeneca stopped work on the molecule in atopic dermatitis one year ago and has seen its peers pull back from the target. GSK dropped its candidate in 2019, and the following year Roche axed a candidate aimed at the IL-33 pathway after seeing asthma data. Sanofi and Regeneron pushed past a setback in phase 2 and powered into a pivotal program in COPD.
The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.